Natural killer cells in cancer immunotherapy
MedComm · 2024-07 · 5 (7)
DOI: 10.1002/mco2.626 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift MedComm, online erschienen am 15.06.2024. Verfasst von DanRu Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Key Lab of Immunity and Inflammation and Institute of Immunology Naval Medical University Shanghai China. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 316 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
Natural killer (NK) cells, as innate lymphocytes, possess cytotoxic capabilities and engage target cells through a repertoire of activating and inhibitory receptors. Particularly, natural killer group 2, member D (NKG2D) receptor on NK cells recognizes stress‐induced ligands—the MHC class I chain‐related molecules A and B (MICA/B) presented on tumor cells and is key to trigger the cytolytic response of NK cells. However, tumors have developed sophisticated strategies to evade NK cell surveillance, which lead to failure of tumor immunotherapy. In this paper, we summarized these immune escaping strategies, including the downregulation of ligands for activating receptors, upregulation of ligands for inhibitory receptors, secretion of immunosuppressive compounds, and the development of apoptosis resistance. Then, we focus on recent advancements in NK cell immune therapies, which include engaging activating NK cell receptors, upregulating NKG2D ligand MICA/B expression, blocking inhibitory NK cell receptors, adoptive NK cell therapy, chimeric antigen receptor (CAR)‐engineered NK cells (CAR‐NK), and NKG2D CAR‐T cells, especially several vaccines targeting MICA/B. This review will inspire the research in NK cell biology in tumor and provide significant hope for improving cancer treatment outcomes by harnessing the potent cytotoxic activity of NK cells.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Key Lab of Immunity and Inflammation and Institute of Immunology Naval Medical University Shanghai China.
- Shanghai Institute of Stem Cell Research and Clinical Translation Dongfang Hospital Shanghai China.
ORCID-Profile: Sheng Xu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Wang, D., Dou, L., Sui, L., Xue, Y., & Xu, S. (2024). Natural killer cells in cancer immunotherapy. MedComm, 5(7). https://doi.org/10.1002/mco2.626
Vancouver
Wang D, Dou L, Sui L, Xue Y, Xu S. Natural killer cells in cancer immunotherapy. MedComm. 2024;5(7). doi:10.1002/mco2.626
BibTeX
@article{Wang2024,
author = {Wang, DanRu and Dou, LingYun and Sui, LiHao and Xue, Yiquan and Xu, Sheng},
title = {Natural killer cells in cancer immunotherapy},
journal = {MedComm},
year = {2024},
volume = {5},
number = {7},
doi = {10.1002/mco2.626}
}
EUVIMED